You are here: Industry Insights > WuXi

News List

WuXi concludes 2013 Life Science Awards in Beijing biospectrumasia
October 29, 2018
WuXi concludes 2013 Life Science Awards in Beijing
WuXi PharmaTech board member steps down biospectrumasia
October 23, 2018
WuXi is now looking for a new board member to replace Ms HanSingapore: Ms Ying Han, member of board of WuXi PharmaTech,
Ligand, WuXi Biologics Amend Agreement contractpharma
July 03, 2018
Ligand Pharmaceuticals has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics. This amendment provides WuXi Bio more efficiency in expanding its OmniAb antibody discovery services.
WuXi STA Enables Ascletis to Receive NDA Approval from China FDA for Ganovo contractpharma
June 19, 2018
STA Pharmaceutical, a subsidiary of WuXi AppTec, said that its partner, Ascletis has received approval from China Food and Drug Administration (CFDA) for its Category 1 new drug, Ganovo, also known as Danoprevir or ASC08, to treat viral hepatitis C.
WuXi, Tsinghua announce strategic partnership biospectrumasia
May 31, 2018
Through this partnership ICIT will have access to WuXi Biologics' comprehensive, integrated services.
WuXi Biologics Expands Operations contractpharma
May 22, 2018
WuXi Biologics revealed plans to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.
WuXi STA to build new R&D center in Shanghai cphi-online
May 10, 2018
STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
WuXi STA Changzhou site passes first FDA inspection cphi-online
May 10, 2018
STA Pharmaceutical's API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the US FDA

Previous page 1 2 3 Next page